Peter Attia· MD
and maybe those are the people where the hscrp shows up very early in the process again I'm completely making this up as an analog to what we see more common ly in in the paths to dementia
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and maybe those are the people where the hscrp shows up very early in the process again I'm completely making this up as an analog to what we see more common ly in in the paths to dementia
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the first and the one with the most evidence is the C reactive protein test – the oldtime markers of inflammation he says can we analyze C reactive protein at here to for trivial not even looked at levels so they started looking at extremely low C reactive protein levels and lo and behold he showed it's beyond debate now that yes they call the test High sensitivity but it's actually the same damn aate it checks for CRP if you have rheumatoid arthritis but the high sensitivity has a different reference range that they relate to atherosclerosis